Notch regulation of tumor angiogenesis

Future Oncology

Volumn 7, Issue 4, 2011, Pages 569-588

  Bridges, Esther ^a   Oon, Chern Ein ^a   Harris, Adrian ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

secretase inhibitor; angiogenesis; Delta like 4; Fringe; growth factor; Jagged1; Notch signaling; VEGF

Indexed keywords

GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GROWTH FACTOR; JAGGED1; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; BLOOD VESSEL; CANCER STEM CELL; CELL TYPE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTINEOPLASTIC AGENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 79953688265     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.20     Document Type: Review

References (215)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl. J. Med. 285(21), 1182-1186 (1971).
2. Artavanis-Tsakonas S, Rand MD, Lake RJ: Notch signaling: cell fate control and signal integration in development. Science 284(5415), 770-776 (1999). (Pubitemid 29291335)
3. Bolós V, Grego-Bessa J, de la Pompa JL: Notch signaling in development and cancer. Endocr. Rev. 28(3), 339-363 (2007). (Pubitemid 46984831)
4. Gerhardt H: VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 4(4), 241-246 (2008).
5. Kamei M, Saunders WB, Bayless KJ, Dye L, Davis GE, Weinstein BM: Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 442(7101), 453-456 (2006). (Pubitemid 44264794)
6. Iruela-Arispe ML, Davis GE: Cellular and molecular mechanisms of vascular lumen formation. Dev. Cell 16(2), 222-231 (2009).
7. Dejana E, Tournier-Lasserve E, Weinstein BM: The control of vascular integrity by endothelial cell junctions: molecular basis and pathological impli cations. Dev. Cell 16(2), 209-221 (2009).
8. Von Tell D, Armulik A, Betsholtz C: Pericytes and vascular stability Exp. Cell Res. 312(5), 623-629 (2006).
9. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996). (Pubitemid 26272076)
10. Bergers G, Benjamin LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3(6), 401-410 (2003). (Pubitemid 37328844)
11. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L: VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7(5), 359-371 (2006).
12. Kappas NC, Zeng G, Chappell JC et al.: The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching. J. Cell Biol. 181(5), 847-858 (2008). (Pubitemid 351786988)
13. Adams RH, Alitalo K: Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol. 8(6), 464-478 (2007). (Pubitemid 46823443)
14. Tammela T, Zarkada G, Wallgard E et al.: Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454(7204), 656-660 (2008).
15. Gaetani P, Hulleman E, Levi D et al.: Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study Tumori 96(1), 97-102 (2010).
16. Gerhardt H, Betsholtz C: Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314(1), 15-23 (2003). (Pubitemid 37409909)
17. Bergers G, Song S: The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 7(4), 452-464 (2005). (Pubitemid 41555617)
18. Kopan R, Ilagan MX: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137(2), 216-233 (2009).
19. Pratt EB, Wentzell JS, Maxson JE, Courter L, Hazelett D, Christian JL: The cell giveth and the cell taketh away: an overview of Notch pathway activation by endocytic traffcking of ligands and receptors. Acta Histochem. 113(3), 248-255 (2011).
20. Brou C, Logeat F, Gupta N et al.: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol. Cell 5(2), 207-216 (2000). (Pubitemid 30628080)
21. Mumm JS, Schroeter EH, S axena MT et al.: A ligand-induced extracellular cleavage regulates γ-secretase-like proteolytic activation of Notch1. Mol. Cell 5(2), 197-206 (2000). (Pubitemid 30628079)
22. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A: Signalling downstream of activated mammalian Notch. Nature 377(6547), 355-358 (1995).
23. Schroeter EH, Kisslinger JA, Kopan R: Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature 393(6683), 382-386 (1998). (Pubitemid 28269713)
24. Nam Y, Sliz P, Song L, Aster JC, Blacklow SC: Structural basis for cooperativity in recruitment of MAML coactivators to Notch transcription complexes. Cell 124(5), 973-983 (2006). (Pubitemid 43344237)
25. Petcherski AG, Kimble J: Mastermind is a putative activator for Notch. Curr. Biol. 10(13), R471-R473 (2000).
26. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffn JD: MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for Notch receptors. Nat. Genet. 26(4), 484-489 (2000).
27. Wu L, Sun T, Kobayashi K, Gao P, Griffn JD: Identifcation of a family of mastermind-like transcriptional coactivators for mammalian notch receptors. Mol. Cell Biol. 22(21), 7688-7700 (2002).
28. Iso T, Kedes L, Hamamori Y: HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell Physiol. 194(3), 237-255 (2003). (Pubitemid 36176887)
29. Lawson ND, Scheer N, Pham VN et al.: Notch signaling is required for arterial-venous differentiation during embryonic vascular developme nt. Development 128(19), 3675-3683 (2001). (Pubitemid 32998917)
30. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S: Crossing paths with Notch in the hyper-network. Curr. Opin. Cell Biol. 19(2), 166-175 (2007). (Pubitemid 46386408)
31. Hofmann JJ, Iruela-Arispe ML: Notch signaling in blood vessels: who is talking to whom about what? Circ Res. 100(11), 1556-1568 (2007). (Pubitemid 46897259)
32. Iso T, Hamamori Y, Kedes L: Notch signaling in vascular development. Arterioscler. Thromb. Vasc Biol. 23(4), 543-553 (2003). (Pubitemid 36438065)
33. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D: Delta4, an endothelial specifc notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 69(2-3), 135-144 (2001). (Pubitemid 33755062)
34. Gale NW, Dominguez MG, Noguera I et al.: Haploinsuffciency of Delta-like 4 l igand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad. Sci. USA 101(45), 15949-15954 (2004). (Pubitemid 39507907)
35. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T: Haploinsuffcient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev. 18(20), 2469-2473 (2004). (Pubitemid 39362888)
36. Benedito R, Trindade A, Hirashima M et al.: Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev. Biol. 8, 117 (2008).
37. Duarte A, Hirashima M, Benedito R et al.: Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev. 18(20), 2474-2478 (2004). (Pubitemid 39362889)
38. Benedito R, Roca C, Sorensen I et al.: The Notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 137(6), 1124-1135 (2009).
39. Xue Y, Gao X, Lindsell CE et al.: Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet. 8(5), 723-730 (1999). (Pubitemid 29189039)
40. High FA, Lu MM, Pear WS, Loomes KM, Kaestner KH, Epstein JA: Endo thelial expression of the Notch ligand Jagged1 is required for vascular smooth muscle development. Proc Natl Acad. Sci. USA 105(6), 1955-1959 (2008). (Pubitemid 351439446)
41. Krebs LT, Xue Y, Norton CR et al.: Notch signaling is essential for vascular morphogenesis in mice. Genes Dev. 14(11), 1343-1352 (2000). (Pubitemid 30397078)
42. Limbourg FP, Takeshita K, Radtke F, Bronson RT, Chin MT, Liao JK: Essential role of endothelial Notch1 in angiogenesis. Circulation 111(14), 1826-1832 (2005). (Pubitemid 40525149)
43. Uyttendaele H, Ho J, Rossant J, Kitajewski J: Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad. Sci. USA 98(10), 5643-5648 (2001). (Pubitemid 32435695)
44. Fischer A, Schumacher N, Maier M, Sendtner M, Gessler M: The Notch target genes HEY1 and HEY2 are required for embryonic vascular development. Genes Dev. 18(8), 901-911 (2004). (Pubitemid 38529659)
45. Takeshita K, Satoh M, Ii M et al.: Critical role of endothelial Notch1 signaling in postnatal angiogenesis. Circ Res. 100(1), 70-78 (2007). (Pubitemid 46066775)
46. Hellstrom M, Phng LK, Gerhardt H: VEGF and Notch signaling: the yin and yang of angiogenic sprouting. Cell Adh. Migr. 1(3), 133-136 (2007).
47. Lobov IB, Renard RA, Papadopoulos N et al.: Delta-li ke ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad. Sci. USA 104(9), 3219-3224 (2007). (Pubitemid 46364140)
48. Harrington LS, Sainson RC, Williams CK et al.: Regulation of mul tiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res. 75(2), 144-154 (2008). (Pubitemid 351249857)
49. Siekmann AF, Lawson ND: Notch signalling limits angiogenic cell behaviour in developing zebrafsh arteries. Nature 445(7129), 781-784 (2007). (Pubitemid 46279717)
50. Suchting S, Freitas C, Le Noble F et al.: The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel b ranching. Proc Natl Acad. Sci. USA 104(9), 3225-3230 (2007). (Pubitemid 46364141)
51. Trindade A, Kumar SR, Scehnet JS et al.: Overexpression of Delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 112(5), 1720-1729 (2008).
52. Schadler KL, Zweidler-Mckay PA, Guan H, Kleinerman ES: Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing 's sarcoma. Clin. Cancer Res. 16(3), 848-856 (2010).
53. Zeng Q, Li S, Chepeha DB et al.: Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 8(1), 13-23 (2005). (Pubitemid 40991811)
54. Veeraraghavalu K, Pett M, Kumar RV et al.: Papillomavirus-mediated neoplastic progression is associated with reciprocal changes in Jagged1 and Manic Fringe expression linked to notch activation. J. Virol. 78(16), 8687-8700 (2004). (Pubitemid 39025134)
55. Veeraraghavalu K, Subbaiah VK, Srivastava S, Chakrabarti O, Syal R, Krishna S: Complementation of human papillomavirus type 16 E6 and E7 by Jagged1-specifc N otch1-phosphatidylinositol 3-kinase signaling involves pleiotropic oncogenic functions independent of CBF1;Su(H);Lag-1 activation. J. Virol. 79(12), 7889-7898 (2005). (Pubitemid 40756825)
56. Ramdass B, Maliekal TT, Lakshmi S et al.: Coexpression of Notch1 and NF-κB signaling pathway components in human cervical cancer progression. Gynecol. Oncol. 104(2), 352-361 (2007). (Pubitemid 46135657)
57. Noseda M, Chang L, Mclean G et al.: Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Mol. Cell Biol. 24(20), 8813-8822 (2004). (Pubitemid 39313888)
58. D'Souza B, Miyamoto A, Weinmaster G: The many facets of Notch ligands. Oncogene 27(38), 5148-5167 (2008).
59. Reedijk M, Odorcic S, Chang L et al.: High-level coexpression of Jag1 and Notch1 is observed in human breast cancer and is associated with p oor overall survival. Cancer Res. 65(18), 8530-8537 (2005). (Pubitemid 41330622)
60. Lin JT, Chen MK, Yeh KT et al.: Association of high levels of Jagged-1 and Notch-1 expression with poor prognosis in head and neck cancer. Ann. Surg. Oncol. 17, 2976-2983 (2010).
61. Chigurupati S, Arumugam TV, Son TG et al.: Involvement of notch signaling in wound healing. PLoS One 2(11), E1167 (2007).
62. Peault B, Rudnicki M, Torrente Y et al.: Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol. Ther. 15(5), 867-877 (2007). (Pubitemid 46621645)
63. Murphy PA, Lam MT, Wu X et al.: Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice. Proc Natl Acad. Sci. USA 105(31), 10901-10906 (2008).
64. Hofmann JJ, Luisa Iruela-Arispe M: Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr. Patterns 7(4), 461-470 (2007). (Pubitemid 46177950)
65. Sorensen I, Adams RH, Gossler A: Dll1-mediated Notch activation regulates endothelial identity in mouse fetal arteries. Blood 113(22), 5680-5688 (2009).
66. Villa N, Walker L, Lindsell CE, Gasson J, Iruela-Arispe ML, Weinmaster G: Vascular expression of Notch p athway receptors and ligands is restricted to arterial vessels. Mech. Dev. 108(1-2), 161-164 (2001). (Pubitemid 32918185)
67. Arboleda-Velasquez JF, Rampal R, Fung E et al.: CADASIL mutations impair Notch3 glycosylation by Fringe. Hum. Mol. Genet. 14(12), 1631-1639 (2005). (Pubitemid 40895515)
68. Louvi A, Arboleda-Velasquez JF, Artavanis-Tsakonas S: CADASIL: a critical look at a Notch disease. Dev. Neurosci. 28(1-2), 5-12 (2006).
69. Oda T, Elkahloun AG, Pike BL et al.: Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat. Genet. 16(3), 235-242 (1997).
70. Kamath BM, Spinner NB, Emerick KM et al.: Vascular anomalies in Alagille syndrome: a signifcant cause of morbidity and mortality. Circulation 109(11), 1354-1358 (2004). (Pubitemid 38387820)
71. Dang TP, Gazdar AF, Virmani AK et al.: Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J. Natl Cancer Inst. 92(16), 1355-1357 (2000). (Pubitemid 30660597)
72. Pece S, Serresi M, Santolini E et al.: Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J. Cell Biol. 167(2), 215-221 (2004). (Pubitemid 39435065)
73. Rao SS, O'Neil J, Liberator CD et al.: Inhibition of Notch signaling by γ secretase inhibitor en gages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res. 69(7), 3060-3068 (2009).
74. Tammam J, Ware C, Efferson C et al.: Down-regulation of the Notch pathway mediated by a γ-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br. J. Pharmacol. 158(5), 1183-1195 (2009).
75. Van Es JH, Van Gijn ME, Riccio O et al.: N otch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435(7044), 959-963 (2005). (Pubitemid 40896322)
76. Li JL, Jubb AM, Harris AL: Targeting Dll4 in tumors shows preclinical activity but potentially signifcant toxicity. Future Oncol. 6(7), 1099-1103 (2010).
77. Jung SG, Kwon YD, Song JA et al.: Prognostic signifcance of Notch 3 gene expression in ovarian serous carcinoma. Cancer Sci. 101(9), 1977-1983 (2010).
78. Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol. Oncol. 117(1), 130-133 (2010).
79. Wang M, Wang J, Wang L, Wu L, Xin X: Notch1 expression correlates with tumor differentiation status in ovarian carcinoma. Med. Oncol. 27(4), 1329-1335 (2010).
80. Reedijk M, Odorcic S, Zhang H et al.: Activation of Notch signaling in human colon adenocarcinoma. Int. J. Oncol. 33(6), 1223-1229 (2008).
81. Westhoff B, Colaluca IN, DArio G et al.: Alterations of the Notch pathway in lung cancer. Proc Natl Acad. Sci. USA 106(52), 22293-22298 (2009).
82. Harrison H, Farnie G, Howell SJ et al.: Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 70(2), 709-718 (2010).
83. Zhang P, Yang Y, Nolo R, Zweidler-Mckay PA, Hughes DP: Regulation of Notch signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness. Oncogene 29(20), 2916-2926 (2010).
84. Hijioka H, Setoguchi T, Miyawaki A et al.: Upregulation of Notch pathway molecules in oral squamous cell carcinoma. Int. J. Oncol. 36(4), 817-822 (2010).
85. Zhao N, Guo Y, Zhang M, Lin L, Zheng Z: AKT-mTOR signaling is involved in Notch-1-mediated glioma cell survival and proliferation. Oncol. Rep. 23(5), 1443-1447 (2010).
86. Ferrando AA: The role of Notch1 signaling in T-ALL. Hematology Am. Soc Hematol. Educ. Program 353-361 (2009).
87. Kamstrup MR, Gjerdrum LM, Biskup E et al.: Notch 1 as a potential therapeutic target in cutaneous T-cell lymphoma. Blood 116(14), 2504-2512 (2010).
88. Wustehube J, Bartol A, Liebler SS et al.: Cerebral cavernous malformation protein CCM1 inhibit s sprouting angiogenesis by activating Delta-Notch signaling. Proc Natl Acad. Sci. USA 107(28), 12640-12645 (2010).
89. Noguera-Troise I, Daly C, Papadopoulos NJ et al.: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444(7122), 1032-1037 (2006). (Pubitemid 46018516)
90. Ridgway J, Zhang G, Wu Y et al.: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444(7122), 1083-1087 (2006). (Pubitemid 46018529)
91. Scehnet JS, Jiang W, Kumar SR et al.: Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 109(11), 4753-4760 (2007). (Pubitemid 46827768)
92. Oishi H, Sunamura M, Egawa S et al.: Blockade of Delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer. Pancreas 39(6), 897-903 (2010).
93. Hoey T, Yen WC, Axelrod F et al.: Dll4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5(2), 168-177 (2009).
94. Li JL, Sainson RC, Shi W et al.: Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 67(23), 11244-11253 (2007). (Pubitemid 350248550)
95. Jubb AM, Buffa FM, Harris AL: Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J. Cell Mol. Med. 14(1-2), 18-29 (2009).
96. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL: Up-regulation of Delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65(19), 8690-8697 (2005). (Pubitemid 41377356)
97. Baliko F, Bright T, Poon R, Cohen B, Egan SE, Alman BA: Inhibition of Notch signaling induces neural differentiation in Ewing sarcoma. Am. J. Pathol. 170(5), 1686-1694 (2007). (Pubitemid 47339313)
98. Pannequin J, Bonnans C, Delaunay N et al.: The Wnt target Jagged-1 mediates the activation of notch signaling by progastrin in human colorectal cancer cells. Cancer Res. 69(15), 6065-6073 (2009).
99. Rodilla V, Villanueva A, Obrador-Hevia A et al.: Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer. Proc Natl Acad. Sci. USA 106(15), 6315-6320 (2009).
100. Guilmeau S, Flandez M, Mariadason JM, Augenlicht LH: Heterogeneity of Jagged1 expression in human and mouse i ntestinal tumors: implications for targeting Notch signaling. Oncogene 29(7), 992-1002 (2010).
101. Shih AH, Holland EC: Notch signaling enhances nestin expression in gliomas. Neoplasia 8(12), 1072-1082 (2006). (Pubitemid 44936157)
102. Radtke F, Raj K: The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer 3(10), 756-767 (2003). (Pubitemid 37328814)
103. Funahashi Y, Hernandez SL, Das I et al.: A Notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res. 68(12), 4727-4735 (2008).
104. Pang RT, Leung CO, Ye TM et al.: MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31(6), 1037-1044 (2010).
105. Reedijk M, Pinnaduwage D, Dickson BC et al.: Jag1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Res. Treat. 111(3), 439-448 (2008).
106. Dickson BC, Mulligan AM, Zhang H et al.: High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod. Pathol. 20(6), 685-693 (2007). (Pubitemid 46788875)
107. Gu F, Ma Y, Zhang Z et al.: Expression of STAT3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol. Rep. 23(3), 671-676 (2010).
108. Sancho R, Jandke A, Davis H, Diefenbacher ME, Tomlinson I, Behrens A: F-box and WD rep eat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsuffcient suppressor of intestinal tumorigenesis. Gastroenterology 139(3), 929-941 (2010).
109. Sikandar SS, Pate KT, Ande rson S et al.: Notch signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 70(4), 1469-1478 (2010).
110. Yao K, Rizzo P, Rajan P et al.: Notch-1 and Notch-4 receptors as prognostic markers in breast cancer. Int. J. Surg. Pathol. DOI: 10.1177/1066896910362080 (2010) (Epub ahead of print).
111. Stylianou S, Clarke RB, Brennan K: Aberrant activation of notch signaling in human breast cancer. Cancer Res. 66(3), 1517-1525 (2006). (Pubitemid 43259933)
112. Ling H, Sylvestre JR, Jolicoeur P: Notch1-induced mammary tumor dev elopment is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors. Oncogene 29(32), 4543-454 (2010).
113. Purow BW, Haque RM, Noel MW et al.: Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res. 65(6), 2353-2363 (2005). (Pubitemid 40490146)
114. Guilmeau S, Flandez M, Mariadason JM, Augenlicht LH: Heterogeneity of Jagged1 expression in human and mouse intestinal tumors: implications for targeting Notch signaling. Oncogene 29(7), 992-1002 (2010).
115. Hanlon L, Avila JL, Demarest RM et al.: Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma. Cancer Res. 70(11), 4280-4286 (2010).
116. Eliasz S, Liang S, Chen Y et al.: Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene 29(17), 2488-2498 (2010).
117. Dotto GP: Notch tumor suppressor function. Oncogene 27(38), 5115-5123 (2008).
118. Xiao X, Ning L, Chen H: Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol. Cancer Ther. 8(2), 350-356 (2009).
119. Patel NS, Dobbie MS, Rochester M et al.: Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin. Cancer Res. 12(16), 4836-4844 (2006). (Pubitemid 44338568)
120. Jubb AM, Turley H, Moeller HC et al.: Expression of Delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br. J. Cancer 101(10), 1749-1757 (2009).
121. Segarra M, Williams CK, Sierra Mde L et al.: Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. Blood 112(5), 1904-1911 (2008).
122. Urs S, Roudabush A, O'Neill CF et al.: Soluble forms of the Notch ligands Delta1 and Jagged1 promote in vivo tumorigenicity in NIH3T3 fbroblasts with distinct phenotypes. Am. J. Pathol. 173(3), 865-878 (2008).
123. Acar M, Jafar-Nejad H, Takeuchi H et al.: Rumi is a CAP10 domain glycosyltransferase that modifes Notch and is required for Notch signaling. Cell 132(2), 247-258 (2008). (Pubitemid 351172433)
124. Moloney DJ, Panin VM, Johnston SH et al.: Fringe is a glycosyltransferase that modifes Notch. Nature 406(6794), 369-375 (2000). (Pubitemid 30625549)
125. Johnston SH, Rauskolb C, Wilson R, Prabhakaran B, Irvine KD, Vogt TF: A family of mammalian Fringe genes i mplicated in boundary determination and the Notch pathway. Development 124(11), 2245-2254 (1997). (Pubitemid 27283245)
126. May WA, Arvand A, Thompson AD, Braun BS, Wright M, Denny CT: EWS/FLI1-induced Manic Fringe renders NIH 3T3 cells tumorigenic. Nat. Genet. 17(4), 495-497 (1997). (Pubitemid 27518406)
127. Lai EC, Tam B, Rubin GM: Pervasive regulation of Drosophila Notch target genes by GY-box-, Brd-box-, and K-box-class microRNAs. Genes Dev. 19(9), 1067-1080 (2005). (Pubitemid 40632452)
128. Kefas B, Comeau L, Floyd D et al.: The neuronal microRNA mirR-326 acts in a feedback loop with Notch and has therapeutic potential against brain tumours. Neurobiol. Dis. 29(48), 15161-15168 (2010).
129. Kennell JA, Gerin I, Macdougald OA, Cadigan KM: The microRNA miR-8 is a conserved negative regulator of Wnt signaling. Proc Natl Acad. Sci. USA 105(40), 15417-15422 (2008).
130. Thatcher EJ, Paydar I, Anderson KK, Patton JG: Regulation of zebrafsh fn regeneration by microRNAs. Proc Natl Acad. Sci. USA 105(47), 18384-18389 (2008).
131. Choi WY, Giraldez AJ, Schier AF: Target protectors reveal dampening and balancing of Nodal agonist and antagonist by miR-430. Science 318(5848), 271-274 (2007). (Pubitemid 47574854)
132. Martello G, Zacchigna L, Inui M et al.: MicroRNA control of nodal signalling. Nature 449(7159), 183-188 (2007). (Pubitemid 47402367)
133. Rogler CE, Levoci L, Ader T et al.: MicroRNA-23b cluster microRNAs regulate transforming growth factor-β/bone morphogenetic protein signaling and liver stem cell differentiation by targeting Smads. Hepatology 50(2), 575-584 (2009).
134. Johnson SM, Grosshans H, Shingara J et al.: RAS is regulated by the let-7 microRNA family. Cell 120(5), 635-647 (2005). (Pubitemid 40343076)
135. Fish JE, Santoro MM, Morton SU et al.: miR-126 regulates angiogenic signaling and vascular integrity. Dev. Cell 15(2), 272-284 (2008).
136. Thum T, Gross C, Fiedler J et al.: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fbroblasts. Nature 456(7224), 980-984 (2008).
137. Kuhnert F, Mancuso MR, Hampton J et al.: Attribution of vascular phenotypes of the murine Egf7 locus to the microRNA miR-126. Development 135(24), 3989-3993 (2008).
138. Meng F, Henson R, Wehb e-Janek H, Ghoshal K, Jacob ST, Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133(2), 647-658 (2007). (Pubitemid 47187346)
139. Huse JT, Brennan C, Hambardzumyan D et al.: The PTEN-regulating microRNA miR-26a is amplifed in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23(11), 1327-1337 (2009).
140. Kato M, Putta S, Wang M et al.: TGF-β activates AKT kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 11(7), 881-889 (2009).
141. Li N, Fu H, Tie Y et al.: miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275(1), 44-53 (2009).
142. Garzia L, Andolfo I, Cusanelli E et al.: MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 4(3), E4998 (2009).
143. Fraisl P, Mazzone M, Schmidt T, Carmeliet P: Regulation of angiogenesis by oxygen and metabolism. Dev. Cell 16(2), 167-179 (2009).
144. Maxwell PH, Ratcliffe PJ: Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol. 13(1), 29-37 (2002). (Pubitemid 35418312)
145. Blancher C Moore JW, Talks KL, Houlbrook S, Harris AL: Relationship of hypoxia-inducible factor (HIF)-1α and HIF-2α expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res. 60(24), 7106-7113 (2000). (Pubitemid 32059191)
146. Ikeda E, Achen MG, Breier G, Risau W: Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 gliom a cells. J. Biol. Chem. 270(34), 19761-19766 (1995).
147. Orimo A, Gupta PB, Sgroi DC et al.: Stromal fbroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121(3), 335-348 (2005). (Pubitemid 40692295)
148. Sparmann A, Bar-Sagi D: Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6(5), 447-458 (2004). (Pubitemid 39469981)
149. Phng LK, Gerhardt H: Angiogenesis: a team effort coordinated by Notch. Dev. Cell 16(2), 196-208 (2009).
150. Claxton S, Fruttiger M: Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr. Patterns 5(1), 123-127 (2004). (Pubitemid 39529808)
151. Diez H, Fischer A, Winkler A et al.: Hypoxia-mediated activation of Dll4-Notch-Hey2 signaling in endothelial progenitor cells and adoption of arterial cell fate. Exp. Cell Res. 313(1), 1-9 (2007). (Pubitemid 44958449)
152. Seo S, Fujita H, Nakano A, Kang M, Duarte A, Kume T: The forkhead transcription factors, FoxC1 and FoxC2, are required for arterial specifcation and lymphatic sprouting during vascular development. Dev. Biol. 294(2), 458-470 (2006). (Pubitemid 43884821)
153. Liu ZJ, Shirakawa T, Li Y et al.: Regulation of Notch1 and Dll4 b y vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol. Cell Biol. 23(1), 14-25 (2003). (Pubitemid 36008497)
154. Williams CK, Li JL, Murga M, Harris AL, Tosato G: Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107(3), 931-939 (2006). (Pubitemid 43156289)
155. Hayashi H, Kume T: Foxc transcription factors directly regulate Dll4 and HEY2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 3(6), E2401 (2008).
156. Taylor KL, Henderson AM, Hughes CC: Notch activation during e ndothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Microvasc Res. 64(3), 372-383 (2002). (Pubitemid 35370739)
157. Mackenzie F, Duriez P, Wong F, Noseda M, Karsan A: Notch4 inhibits endothelial apoptosis via RBP-J-dependent and-independent pathways. J. Biol. Chem. 279(12), 11657-11663 (2004). (Pubitemid 38401668)
158. Shawber CJ, Funahashi Y, Francisco E et al.: Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. J. Clin. Invest. 117(11), 3369-3382 (2007). (Pubitemid 350096993)
159. Wang T, Holt CM, Xu C et al.: Notch3 activation modulates cell growth behaviour and cross-talk to Wnt/TCF signalling pathway. Cell Signal 19(12), 2458-2467 (2007). (Pubitemid 47531927)
160. Yamamizu K, Matsunaga T, Uosaki H et al.: Convergence of Notch and β-catenin signaling induces arterial fate in vascular progenitors. J. Cell Biol. 189(2), 325-338 (2010).
161. Coant N, Ben Mkaddem S, Pedruzzi E et al.: NADPH oxidase 1 modulates WNT and Not ch1 signaling to control the fate of proliferative progenitor cells in the colon. Mol. Cell Biol. 30(11), 2636-2650 (2010).
162. Corada M, Nyqvist D, Orsenigo F et al.: The Wnt/β-catenin pathway modulates vascular remodeling and specifcation by upregulating Dll4/Notch signaling. Dev. Cell 18(6), 938-949 (2010).
163. Katoh M: Notch ligand, Jag1, is evolutionarily conserved target of canonical Wnt signaling pathway in progenitor cells. Int. J. Mol. Med. 17(4),
164. Sainson RC, Johnston DA, Chu HC et al.: TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood 111(10), 4997-5007 (2008).
165. Suzuki M, Yamamoto M, Sugimoto A, Nakamura S, Motoda R, Orita K: Delta-4 expression on a stromal cell line is augmented by interleukin-6 via STAT3 activat ion. Exp. Hematol. 34(9), 1143-1150 (2006).
166. Kiec-Wilk B, Grzybowska-Galuszka J, Polus A, Pryjma J, Knapp A, Kristiansen K: The MAPK-dependent regulation of the Jagged/Notch gene expression by VEGF, bFGF or PPAR γ mediated angiogenesis in HUVEC. J. Physiol. Pharmacol. 61(2), 217-225 (2010).
167. Almog N: Molecular mechanisms underlying tumor dormancy. Cancer Lett. 294(2), 139-146 (2010).
168. Moserle L, Amadori A, Indraccolo S: The angiogenic switch: implications in the regulation of tumor dormancy. Curr. Mol. Med. 9(8), 935-941 (2009).
169. Aguirre-Ghiso JA: Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 7(11), 834-846 (2007). (Pubitemid 350006258)
170. Indraccolo S, Minuzzo S, Masiero M et al.: Cross-talk between tumor and endothelial cells involvi ng the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res. 69(4), 1314-1323 (2009).
171. Prakash N, Hansson E, Betsholtz C, Mitsiadis T, Lendahl U: Mouse Notch 3 expression in th e pre-and postnatal brain: relationship to the stroke and dementia syndrome CADASIL. Exp. Cell Res. 278(1), 31-44 (2002). (Pubitemid 34775443)
172. Wang T, Baron M, Trump D: An overview of Notch3 function in vascular smooth muscle cells. Prog. Biophys. Mol. Biol. 96(1-3), 499-509 (2008). (Pubitemid 351635621)
173. Leek RD, Talks KL, Pezzella F et al.: Relation of hypoxia-inducible factor-2 a (HIF-2 a) expression in tumor-infltrative macrophages t o tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 62(5), 1326-1329 (2002). (Pubitemid 34407787)
174. Sivridis E, Giatromanolaki A, Anastasiadis P et al.: Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J. Pathol. 196(4), 416-422 (2002). (Pubitemid 34262853)
175. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J. Pathol. 196(3), 254-265 (2002). (Pubitemid 34189413)
176. Lin WW, Karin M: A cytokine-mediated link between innate immunity, infammation, and cancer. J. Clin. Invest. 117(5), 1175-1183 (2007). (Pubitemid 46718402)
177. Murdoch C, Giannoudis A, Lewis CE: Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104(8), 2224-2234 (2004). (Pubitemid 39331817)
178. Leek RD, Landers RJ, Harris AL, Lewis CE: Necrosis correlates with high vascular density and focal macrophage infltration in invasive carcinoma of the breast. Br. J. Cancer 79(5-6), 99 1-995 (1999).
179. Negus RP, Stamp GW, Hadley J, Balkwill FR: Quantitative assessment of the leukocyte infltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150(5), 1723-1734 (1997). (Pubitemid 27193819)
180. Ohno S, Ohno Y, Suzuki N et al.: Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 24(5C), 3335-3342 (2004). (Pubitemid 39390949)
181. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res. 66(2), 605-612 (2006). (Pubitemid 43165918)
182. Fung E, Tang SM, Canner JP et al.: Delta-like 4 induces notch signaling in macrophages: implications for infammation. Circulation 115(23), 2948-2956 (2007). (Pubitemid 46912098)
183. Simons M, Raposo G: Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21(4), 575-581 (2009).
184. Hood JL, Pan H, Lanza GM, Wickline SA: Paracrine induction of endothelium by tumor exosomes. Lab. Invest. 89(11), 1317-1328 (2009).
185. Sheldon H, Heikamp E, Turley H et al.: New mechanism for Notch signaling to endothelium at a distance by Delta-like 4 incorporation into exosomes. Blood 116(13), 2385-2394 (2010).
186. Sainson RC, Aoto J, Nakatsu MN et al.: Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J. 19(8), 1027-1029 (2005). (Pubitemid 40827740)
187. Weijzen S, Velders MP, Elmishad AG et al.: The Notch ligand Jagged-1 is able to induce maturation of monocyte-derived human dendritic cells. J. Immunol. 169(8), 4273-4278 (2002). (Pubitemid 35178199)
188. Hellstrom M, Phng LK, Hofmann JJ et al.: Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445(7129), 776-780 (2007). (Pubitemid 46279716)
189. Boyer-Di Ponio J, Wr ight-Crosnier C, Groyer-Picard MT et al.: Biological function of mutant forms of JAGGED1 proteins in Alagille syndrome: inhibitory effect on Notch signaling. Hum. Mol. Genet. 16(22), 2683-2692 (2007).
190. Ste iner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C: Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastoma multiforme: clinical relevance of radiation-induced increase of VEGF levels. J. Neurooncol. 66(1-2), 129-138 (2004). (Pubitemid 38258367)
191. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM: Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth facto r expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3́-kinase and distinct from that induced by hypoxia. Cancer Res. 60(20), 5879-5886 (2000).
192. Wesseling P, Van Der Laak JA, De Leeuw H, Ruiter DJ, Burger PC: Quantitative immunohistological analysis of the microvasculature in untreated human glioblastoma multiforme. Computer-assisted image analysis of whole-tumor sections. J. Neurosurg. 81(6), 902-909 (1994). (Pubitemid 24373471)
193. Nowacki P, Kojder I: Peritumoral angiogenesis around primary and metastatic brain neoplasms. Morphometric analysis. Folia Neuropathol. 39(2), 95-102 (2001).
194. Ricci-Vitiani L, Pallini R, Biffoni M et al.: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824-828 (2010).
195. Wang R, Chadalavada K, Wilshire J et al.: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833, (2010).
196. Charles N, Holland EC: The perivascular niche microenvironment in brain tumor progression. Cell Cycle 9(15), 3012-3021 (2010).
197. Leslie JD, Ariza-Mcnaughton L, Bermange AL, Mcadow R, Johnson SL, Lewis J: Endothelial signalling by the Notch ligand Delta-like 4 restricts angioge nesis. Development 134(5), 839-844 (2007). (Pubitemid 46795675)
198. Thurston G, Noguera-Troise I, Yancopoulos GD: The Delta paradox: Dll4 blockade leads to more tumour vessels but less tumour growth. Nat. Rev. Cancer 7(5), 327-331 (2007). (Pubitemid 46652486)
199. Sainson RC, Harris AL: Anti-Dll4 therapy: can we block tumour growth by increasing angiogenesis? Trends Mol. Med. 13(9), 389-395 (2007). (Pubitemid 47385383)
200. Jain RK, Duda DG, Clark JW, Loeffer JS: Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006). (Pubitemid 43108832)
201. Ferrara N, Kerbel RS: Angiogenesis as a therapeutic target. Nature 438(7070), 967-974 (2005). (Pubitemid 43093963)
202. Shih IM, Wang TL: Notch signaling, g-secretase inhibitors, and cancer therapy Cancer Res. 67(5), 1879-1882 (2007).
203. Wei P, Walls M, Qiu M et al.: Evaluation of selective g-secretase inhibitor PF-03084014 for its antitumor effcacy and gastrointestinal safety to guide optimal clinical trial design. Mol. Cancer Ther. 9(6), 1618-1628 (2010).
204. Hallahan AR, Pritchard JI, Hansen S et al.: The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res. 64(21), 7794-7800 (2004). (Pubitemid 39446912)
205. Yan M, Callahan CA, Beyer JC et al.: Chronic Dll4 blockade induces vascular neoplasms. Nature 463(7282), E6-E7 (2010).
206. Beel AJ, Barrett P, Schnier PD et al.: Nonspecifcity of binding of γ-secretase modulators to the amyloid precursor protein. Biochemistry 48(50), 11837-11839 (2009).
207. Wu Y, Cain-Hom C, Choy L et al.: Therapeutic antibody targeting of individual Notch receptors. Nature 464(7291), 1052-1057 (2010).
208. Haller BK, Brave A, Wallgard E et al.: Therapeutic effcacy of a DNA vaccine targeting the endothelial tip cell antigen Delta-like ligand 4 in mammary carcinoma. Oncogene 29(30), 4276-4286 (2010).
209. Wang Z, Li Y, Ahmad A et al.: Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim. Biophys. Acta 1806(2), 258-267 (2010).
210. Zang S, Chen F, Dai J et al.: RNAi-mediated knockdown of Notch-1 leads to cell growth inhibition and enhanced chemosensitivity in human breast cancer. Oncol. Rep. 23(4), 893-899 (2010).
211. Efferson CL, Winkelmann CT, Ware C et al.: Downregulation of Notch pathway by a γ-secretase inhibitor attenuates AKT/mammalian target of rapamy cin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res. 70(6), 2476-2484 (2010).
212. Aste-Amezaga M, Zhang N, Lineberger JE et al.: Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptors. PLoS One 5(2), E9094 (2010).
213. Benjamin LE, Hemo I, Keshet E: A plasticity window for blood vessel remodelling is defned by pericyte cov erage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125(9), 1591-1598 (1998). (Pubitemid 28256727)
214. Erber R, Thurnher A, Katsen AD et al.: Combined inhibition of VEGF and PDGF s ignaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 18(2), 338-340 (2004).
215. Song N, Huang Y, Shi H et al.: Overexpression of platelet-derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1α/CXCR4 axis. Cancer Res. 69(15), 6057-6064 (2009).